SHTDF (Sinopharm Group Co) Beneish M-Score: -2.47 (As of Jun. 25, 2026)

What is Sinopharm Group Co Beneish M-Score?

Sinopharm Group Co SHTDF -2.67% 78 Beneish M-Score is -2.47 as of Jun. 25, 2026. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $2.99 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 113 Medical Distribution companies, Sinopharm Group Co ranks better than 53.1% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.47 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sinopharm Group Co's Beneish M-Score or its related term are showing as below:

SHTDF' s Beneish M-Score Range Over the Past 10 Years
Min: -2.76 Med: -2.46 Max: -2.26
Current: -2.47

During the past 13 years, the highest Beneish M-Score of Sinopharm Group Co was -2.26. The lowest was -2.76. And the median was -2.46.

Sinopharm Group Co Beneish M-Score Related Terms

Sinopharm Group Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Sinopharm Group Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinopharm Group Co Beneish M-Score Chart

Sinopharm Group Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Beneish M-Score

Get a 7-Day Free Trial

-2.31

-2.76

-2.49

-2.45

-2.47

Sinopharm Group Co Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Beneish M-Score	Get a 7-Day Free Trial															-2.49	0.00	-2.45	0.00	-2.47

SHTDF vs MCK, COR, CAH: Beneish M-Score Comparison

For the Medical Distribution subindustry, Sinopharm Group Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinopharm Group Co Beneish M-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's Beneish M-Score falls into.

Save Embed

78GF Score

Sinopharm Group Co Ltd SHTDF

Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Sinopharm Group Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sinopharm Group Co for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 1.0401

0.528 * 1.045

0.404 * 0.9896

0.892 * 1.0172

0.115 * 1.0147

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 0.9545

4.679 * -0.017889

0.327 * 0.9702

-2.47

This Year (Dec25) TTM:

Last Year (Dec24) TTM:

Total Receivables was $30,040 Mil.
Revenue was $81,663 Mil.
Gross Profit was $5,917 Mil.
Total Current Assets was $49,238 Mil.
Total Assets was $55,424 Mil.
Property, Plant and Equipment(Net PPE) was $2,308 Mil.
Depreciation, Depletion and Amortization(DDA) was $609 Mil.
Selling, General, & Admin. Expense(SGA) was $3,410 Mil.
Total Current Liabilities was $35,030 Mil.
Long-Term Debt & Capital Lease Obligation was $872 Mil.
Net Income was $1,016 Mil.
Gross Profit was $0 Mil.
Cash Flow from Operations was $2,007 Mil.

Total Receivables was $28,393 Mil.
Revenue was $80,282 Mil.
Gross Profit was $6,078 Mil.
Total Current Assets was $47,722 Mil.
Total Assets was $53,955 Mil.
Property, Plant and Equipment(Net PPE) was $2,419 Mil.
Depreciation, Depletion and Amortization(DDA) was $650 Mil.
Selling, General, & Admin. Expense(SGA) was $3,512 Mil.
Total Current Liabilities was $34,389 Mil.
Long-Term Debt & Capital Lease Obligation was $1,634 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(30039.628 / 81662.863)	/	(28393.028 / 80281.831)
	=	0.367849	/	0.353667
	=	1.0401

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(6078.453 / 80281.831)	/	(5916.631 / 81662.863)
	=	0.075714	/	0.072452
	=	1.045

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (49238.395 + 2308) / 55423.843)	/	(1 - (47721.726 + 2419.007) / 53955.148)
	=	0.06996	/	0.070696
	=	0.9896

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	81662.863	/	80281.831
	=	1.0172

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(650.17 / (650.17 + 2419.007))	/	(608.964 / (608.964 + 2308))
	=	0.211839	/	0.208766
	=	1.0147

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(3410.231 / 81662.863)	/	(3512.325 / 80281.831)
	=	0.04176	/	0.04375
	=	0.9545

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((871.845 + 35030.324) / 55423.843)	/	((1633.979 + 34388.944) / 53955.148)
	=	0.647775	/	0.667646
	=	0.9702

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(1015.887 - 0	-	2007.355)	/	55423.843
	=	-0.017889

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sinopharm Group Co has a M-score of -2.47 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of -2.47 mean?

Sinopharm Group Co (SHTDF) has a Beneish M-Score of -2.47 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sinopharm Group Co and its competitors. According to the industry distribution chart, Sinopharm Group Co ranks #53 out of 113 companies in the Medical Distribution industry, placing it in the top 46.9%.

Is Sinopharm Group Co's Beneish M-Score too high?

Sinopharm Group Co's current Beneish M-Score is -2.47. Based on the distribution chart, Sinopharm Group Co ranks #53 out of 113 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Sinopharm Group Co's Beneish M-Score compare to MCK and COR?

According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #53 out of 113 companies for Beneish M-Score. This puts Sinopharm Group Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Medical Distribution company?

A good Beneish M-Score depends on the Medical Distribution industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Sinopharm Group Co and its competitors. Sinopharm Group Co's current Beneish M-Score is -2.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sinopharm Group Co stock overvalued right now?

Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.99, compared to a current price of $2.29 — trading 23.5% below its estimated fair value. The current Beneish M-Score is -2.47. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current Beneish M-Score is -2.47 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinopharm Group Co (SHTDF) Overvalued in 2026?

Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued. The current stock price of $2.29 is trading 23.5% below its estimated GF Value™ of $2.99. GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.

Key valuation signals for SHTDF:

Beneish M-Score: -2.47
GF Value™: $2.99 vs. price of $2.29 (23.5% below fair value)
GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinopharm Group Co Business Description

Industry Healthcare Medical Distribution

Comparable Companies HKSE:02656 HKSE:01931 HKSE:00314 HKSE:00673 HKSE:02289 HKSE:09955 HKSE:06833 HKSE:00401 HKSE:08223 HKSE:00718 MCK COR CAH ASX:SIG HSIC SHSE:601607 XSWX:GALE SHSE:600332 SHSE:600998 TSE:7459

Other Exchanges SHTDY:USA 01099:Hong Kong X2S:Germany

Address No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023

Website http://www.sinopharmgroup.com.cn

Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

78GF Score

Get the complete analysis for SHTDF

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.29

Price

$2.99

GF Value

View SHTDF Analysis

See Beneish M-Score data for all stocks →